Federal healthcare policy shapes how medicines are approved, how insurance markets operate, and how patients access care across the country.
Patients Rising works with policymakers, advocates, and healthcare leaders to advance federal policies that lower patient costs, strengthen program accountability, and expand access to medical innovation.
Congress and federal agencies play a major role in shaping the healthcare system. Federal policies determine how medicines are evaluated, how insurance markets operate, and how healthcare programs serve patients across the country.
Legislation and regulatory actions influence everything from prescription drug pricing to insurance benefit design and the approval of innovative medical treatments.
Patients Rising engages in federal policy debates to ensure patients have a voice in the decisions that shape access to care.
Patients Rising supports legislation prohibiting the use of Quality Adjusted Life Years (QALYs) in federal healthcare programs to ensure patients with disabilities and chronic illness are not disadvantaged in coverage decisions.
The 340B drug pricing program allows hospitals to purchase medicines at steep discounts intended to support vulnerable patients. Greater transparency and oversight are needed to ensure the program delivers measurable benefits for the patients it was designed to help.
Federal drug price negotiation policies aim to reduce prescription drug costs while raising complex questions about long-term innovation and patient access to treatments.
International reference pricing proposals tie U.S. medicine prices to those in other countries, raising concerns about how such policies could affect medical innovation and future drug development.
Recent federal reforms targeting PBM practices aim to increase transparency in the prescription drug supply chain and improve how prescription drug benefits operate for patients.
This legislation supports continued investment in biotechnology and medical innovation, helping ensure the United States remains a global leader in developing new medical technologies.
The DOC Access Act addresses abusive practices in dental and vision insurance markets by preventing insurers from setting fees for non-covered services and restricting provider laboratory choices.